



CME Session 8

Oncology & Theranostics Committee

Monday, October 19, 16:45–18:15

Session Title

The Evidence Shift: Impact of Prospective Imaging Trials in Oncology

Wolfgang Fendler (Essen, Germany)

Géraldine Gebhart (Brussels, Belgium)

Programme

16:45–17:05	Lena Unterrainer (Munich, Germany): FAP Imaging in Oncology
17:05–17:30	Géraldine Gebhart (Brussels, Belgium): FDG PET-Guided Randomised Trials
17:30–17:55	Caner Civan (Istanbul, Türkiye): Molecular Imaging Biomarkers of Outcome: PSMA, FAP, FDG, SSTR and more
17:55–18:15	Andrea Farolfi (Bologna, Italy): Novel Imaging in Phase I/II: CA9, GRPR and New Cancer Targets

Educational Objectives

1. Describe the design, methodology, and key outcomes of recent prospective molecular imaging trials across major oncologic tracers, including FDG, PSMA, FAP, and SSTR.
2. Assess the clinical impact of imaging-guided trial evidence on patient management and decision-making in oncology, with a focus on staging, risk stratification, and therapy guidance.
3. Recognise emerging molecular imaging targets and early-phase trial data (e.g. FAP, CAIX, GRPR) and evaluate their potential influence on future clinical practice.

Summary

Prospective and randomised imaging trials are increasingly shaping clinical decision-making in oncologic nuclear medicine. This CME session provides a comprehensive update on key imaging studies that are actively changing clinical practice, covering established approaches such as FDG PET-guided randomised trials alongside novel tracers and targets including PSMA, FAP, SSTR, CAIX, and GRPR. Expert speakers will review methodological aspects, clinical endpoints, and outcome-relevant biomarkers derived from prospective trials, highlighting how molecular imaging contributes to improved staging, prognostication, and treatment selection. The session aims to bridge key trial evidence and real-world clinical implementation, providing participants with an understanding of how contemporary imaging trials are redefining standards of care in oncology.

Key Words

Molecular Imaging; Prospective Imaging Trials; Randomised Clinical Trials; FDG; PSMA; FAP; SSTR; Oncology; Theranostics